NCT05624853View on ClinicalTrials.gov

A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 12, 2020

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Neuropathic PainDiabetes Mellitus, Type 2
Interventions
DRUG

pregabalin sustained release tablet

pregabalin sustained release tablet 150mg qd for 8weeks

DRUG

pregabalin immediate release capsule

pregabalin immediate release capsule 75mg bid for 8weeks

Trial Locations (8)

14647

Catholic University of Korea's Bucheon St. Mary's Hospital, Bucheon-si

28644

Chungbuk National University Hospital, Cheongju-si

30099

Chungnam National University Sejong Hospital, Sejong

31116

Dankook University Hospital, Cheonan

35015

Chungnam National University Hospital, Daejeon

35233

Daejeon Eulji Medical Center, Eulji University, Daejeon

48108

Inje University Haeundae Paik Hospital, Busan

49267

Kosin University Gospel Hospital, Busan

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT05624853 - A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain | Biotech Hunter | Biotech Hunter